end of the infusion or approximately 4 hours after cessation of the infusion.
In accordance with Glantz et al. ( I ) , we did not measure significant concentrations in the CSF of one patient in whom CSF was sampled. In another patient, we could examine a small sample of normal brain tissue, and we were not able to demonstrate paclitaxel. With respect to tumor tissue concentrations, however, our findings differed significantly from the findings of Glantz et al. ( I ) , with tissue concentrations ranging from 464 to 2000 ng/g in all three patients. In two of our three patients, tumor tissue levels were significantly higher than plasma levels (tumor, 2000 ng/g; plasma, 160 ng/mL; tumor, 464 ng/g; and plasma, 211 ng/mL). Paclitaxel identity in tumor tissue was confirmed on the basis of the HPLC retention time and its ultraviolet spectroscopic properties as analyzed by photo-diode array detection in line with the HPLC system.
It is not quite clear how these different findings should be explained. Possibly, technical differences in the method of analysis might play a role, but also of importance may be the fact that Glantz et al. examined rat tumors and we examined human tumors. Lesser et al. (3) demonstrated that disruption of the blood-brain bamer in rats by the presence of tumor leads to relatively high intratumoral paclitaxel concentrations. Our three patients had been operated on and had received radiotherapy in the past, which probably disrupted the blood-brain barrier.
In a phase I1 protocol, Chamberlain et al. (4) recently demonstrated modest efficacy of paclitaxel in patients with recurrent primary brain tumors. On the basis of these results and on our data, we think that there still might be a rationale for paclitaxel, also in combination with radiotherapy, in the treatment of CNS malignancies.
Response
Thank you for forwarding us the letter by Heimans et al. We are well aware of their extensive pharmacologic studies related to paclitaxel (Taxol) but unfortunately were unaware of their publication in the Annals of Oncology when we submitted our manuscript to the Journal of the National Cancer Institute. We are pleased that our results concur with theirs concerning concentrations of paclitaxel in cerebrospinal fluid. We note with interest the high concentrations of paclitaxel in tumors compared with those in plasma; however, we cannot explain the differences between the concentrations in tumor tissue measured by them and by us. Although the assay employed by Heimans and colleagues is more sensitive than that used in our study, the concentrations of paclitaxel reported by them should have been detectable if present in the tumor tissue we studied. We also cannot comment on the differences between implanted rat tumors and primary, human neoplasms. It is a reasonable hypothesis that disruption of the blood-brain barrier in the patients from The Netherlands contributed to the higher intratumoral concentration. We also agree with Heimans et al. that pharmacology data are not a substitute for a well-performed clinical trial and that their data, those of Lesser et al. (I) , and ours are not substitutes for patient response data. While the data reported by Chamberlain et al. (2) are encouraging, the ultimate use of paclitaxel in central nervous system malignancies, and possibly even the most appropriate dose and schedule for its administration, will require more extensive clinical evaluation. 
Re: Long-Term Tamoxifen Treatment for Breast Cancer
Greenspan (1) points out that the review of my book (2) by Fabian (3) did not focus on the apparent association of tamoxifen with the detection of endometrial cancer. Greenspan quite rightly points out that there has been little balance in the reporting of concerns about tarnoxifen. The reports of the association of tamoxifen with endometrial cancer (45) and its prognosis (6) are now known to be flawed or inappropriately reported. Obviously, a book review cannot cover all ground, but the answer to Dr. Greenspan's questions has been published elsewhere (7) (8) (9) (10) There is nothing in the priorities of the government and the Parliament that indicates increased funding for basic research in the foreseeable future. This funding situation will lead to a collapse of cancer research-related projects in Russia, with negative consequences for the international scientific community.
There already has been a "brain drain" from our institute, with many young scientists going to more profitable businesses or leaving for other countries. We want to stay and work in Russia. Therefore, we appeal to the international scientific community to consider the possibilities of grants for cooperative research with the N. N. Petrov Institute. This letter should not be seen as an appeal for humanitarian aid. Our qualifications and experience in collaboration with international research centers will allow us to respond to your proposals or to suggest new projects for cooperative work and to conduct them efficiently. We look forward to hearing from and working with the international cancer research community. 
